LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

Home・Listă Acțiuni・Novartis AG

Novartis AG

Închisă

150.46 0.06

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

150

Maxim

151.62

Indicatori cheie
By Trading Economics
Venit	747M 3.2B
Vânzări	189M 14B
P/E Medie Sector	21.368 49.701
EPS	1.65
Randament dividend	3.18
Marjă de profit	23.336
Angajați	75,267
EBITDA	338M 5.4B

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+11.05% upside

Dividende
By Dow Jones
Randament dividend Medie Sector	3.18% 2.39%

Statistici piață
By TradingEconomics
Capitalizare de piață	6.3B 285B
Deschiderea anterioară	150.4
Închiderea anterioară	150.46

Scor tehnic

By Trading Central

Încredere

Bearish Evidence

N/A / 112.63 Suport & Rezistență

Novartis AG Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

28 apr. 2026, 09:05 UTC

Câștiguri

Novartis Earnings Hit by Generic Competition -- Update

28 apr. 2026, 05:51 UTC

Câștiguri

Novartis Could Upgrade Future Growth Outlook

27 mar. 2026, 10:24 UTC

Achiziții, Fuziuni, Preluări

Novartis to Buy Allergy-Drug Developer Excellergy for Up to $2 Billion -- Update

27 mar. 2026, 06:36 UTC

Achiziții, Fuziuni, Preluări

Novartis to Buy Biotech Excellergy for Up to $2 Billion

28 apr. 2026, 09:18 UTC

Market Talk

Câștiguri

European Pharma Stocks Slip After Novartis Books Sales, Profit Drop -- Market Talk

28 apr. 2026, 07:26 UTC

Market Talk

Câștiguri

Novartis's Results Are Mixed -- Market Talk

28 apr. 2026, 05:07 UTC

Câștiguri

Novartis: Multiple Drug Readouts in 2H Could Raise Mid- to Long-Term Growth Outlook

28 apr. 2026, 05:05 UTC

Câștiguri

Novartis: On Track to Deliver Full-Year Guiance

28 apr. 2026, 05:04 UTC

Câștiguri

Novartis Sees 2026 Core Operating Income Declining by Low Single-digit

28 apr. 2026, 05:04 UTC

Câștiguri

Novartis Sees 2026 Net Sales Growing by Low Single-digit

28 apr. 2026, 05:03 UTC

Câștiguri

Novartis 1Q Core EPS $1.99

28 apr. 2026, 05:03 UTC

Câștiguri

Analysts Saw Novartis 1Q Core Operating Profit at $5.1B

28 apr. 2026, 05:02 UTC

Câștiguri

Novartis 1Q Core Operating Profit $4.90B

28 apr. 2026, 05:02 UTC

Câștiguri

Analysts Saw Novartis 1Q Sales at $13.34B

28 apr. 2026, 05:01 UTC

Câștiguri

Novartis 1Q Sales $13.11B

28 apr. 2026, 05:00 UTC

Câștiguri

Novartis Backs 2026 View

28 apr. 2026, 05:00 UTC

Câștiguri

Novartis AG 1Q EPS $1.65

28 apr. 2026, 05:00 UTC

Câștiguri

Novartis AG 1Q Net Pft $3.2B

28 apr. 2026, 05:00 UTC

Câștiguri

Novartis AG 1Q Adj EPS $1.99

24 apr. 2026, 05:20 UTC

Câștiguri

Novartis Is Making Coartem Available on Largely Not-For-Profit Basis in Malaria-Endemic Regions

24 apr. 2026, 05:19 UTC

Câștiguri

Novartis: Process Is to Assess Quality, Safety and Efficacy of Treatments

24 apr. 2026, 05:19 UTC

Câștiguri

Novartis: Prequalification Is a Process Run by the WHO

10 apr. 2026, 11:45 UTC

Market Talk

Novartis Investors to Focus on Pipeline Update Amid Weak Results -- Market Talk

2 apr. 2026, 08:01 UTC

Market Talk

Novartis Likely to Confirm Guidance -- Market Talk

30 mar. 2026, 09:37 UTC

Market Talk

Novartis to Take Earnings Hit From Generic Competition -- Market Talk

27 mar. 2026, 07:54 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Novartis's Excellergy Payments Should Be Back-End Loaded -- Market Talk

27 mar. 2026, 06:22 UTC

Achiziții, Fuziuni, Preluări

Correct: Novartis Will Pay Up to $2B Upfront, and Milestone Payments

27 mar. 2026, 06:05 UTC

Achiziții, Fuziuni, Preluări

Novartis: Transaction Is Expected to Close in 2H 2026, Subject to Approvals

27 mar. 2026, 06:04 UTC

Achiziții, Fuziuni, Preluări

Novartis Will Pay Up to $2B Upfront Followed by Milestone Payments

27 mar. 2026, 06:03 UTC

Achiziții, Fuziuni, Preluări

Novartis: Exl-111 Is a Half-Life Extended, High-Affinity anti-IgE Antibody in Phase 1

Comparație

Modificare preț

Novartis AG Așteptări

Obiectiv de preț

By TipRanks

11.05% sus

Prognoză pe 12 luni

Medie 167.07 USD 11.05%

Maxim 180 USD

Minim 141 USD

În baza a 5 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruNovartis AG - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

5 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 5 analiști care au acordat evaluări ale acțiunilor Novartis AG - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

N/A / 112.63Suport & Rezistență

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bullish.

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Novartis AG

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.